Use of the drug aleglitazar, which has shown the ability to lower glucose levels and have favorable effects on cholesterol, did not reduce the risk of cardiovascular death, heart attack or stroke among patients with type 2 diabetes and recent heart attack or unstable angina, according to a study.<img src="http://feeds.feedburner.com/~r/sciencedaily/~4/Zvw8OpEaOlk" height="1" width="1"/>
